Fentanyl titration for cancer pain: continuous subcutaneous injection and a once-daily transdermal patch – case series

Sakaguchi, Tatsuma; Kajiyama, Toru; Miyake, Mafumi; Katayama, Toshiro

doi:10.1136/bmjspcare-2022-003720

Cited by 2 publications

(2 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our protocol for opioid titration has been described elsewhere 9. Briefly, the hydromorphone concentration was fixed to 0.2 mg/mL or 2 mg/mL in 10 mL of physiological (0.9%) saline.…”

Section: Methodsmentioning

confidence: 99%

Hydromorphone for dyspnoea in terminally ill patients with cancer: case series

Sakaguchi

Kajiyama

2022

BMJ Support Palliat Care

Self Cite

View full text Add to dashboard Cite

ObjectiveOpioids can mitigate dyspnoea, but the efficacy of hydromorphone use for dyspnoea in patients with cancer is not well known.MethodsPatients with cancers with more than mild dyspnoea treated with subcutaneous injection of hydromorphone between March 2020 and February 2022 at Kitano Hospital (Osaka, Japan) were reviewed retrospectively. Only patients who could self-report their symptoms ≥3 days after the start of hydromorphone therapy were included. Dyspnoea severity was rated on a five-point scale (0: ‘not bothersome'; 1: ‘mild’; 2: ‘moderate’; 3: ‘severe’; 4: ‘overwhelming’).ResultsFifteen patients (2 with moderate, 12 with severe and 1 with overwhelming dyspnoea) were deemed eligible. The median interval from the start of hydromorphone initiation to death was 19 (IQR, 11–37) days. Thoracic drainage and palliative sedation after the start of hydromorphone therapy was undertaken in three and two patients, respectively. At 3 days, the median score of the Dyspnoea Rating Scale was improved significantly from 3 to 2 compared with that at baseline (p=0.0023). The intensity of dyspnoea was improved in 11 patients (73%). Opioid-related adverse events were not observed within 3 days.ConclusionsUsing hydromorphone for dyspnoea in patients with cancer seems to be appropriate if morphine use is contraindicated.

show abstract

“…Our protocol for opioid titration has been described elsewhere 9. Briefly, the hydromorphone concentration was fixed to 0.2 mg/mL or 2 mg/mL in 10 mL of physiological (0.9%) saline.…”

Section: Methodsmentioning

confidence: 99%

Hydromorphone for dyspnoea in terminally ill patients with cancer: case series

Sakaguchi

Kajiyama

2022

BMJ Support Palliat Care

Self Cite

View full text Add to dashboard Cite

show abstract

“…Fentanyl citrate (Terumo, Tokyo, Japan) was administered by continuous injection via the subcutaneous route in three patients and by a transdermal patch (Fentos Tape; Hisamitsu Pharmaceutical, Tokyo, Japan) in three patients. The method of fentanyl titration via the subcutaneous route, followed by the patch has been described elsewhere 2. A compact syringe driver (Terufusion TE-361; Terumo) was used, and a 24 G plastic catheter was placed subcutaneously in the abdomen.…”

mentioning

confidence: 99%